Premium Content:

Experts pour cold water on claims of potential HIV cure

HIV experts have dismissed suggestions that a new drug could potentially lead to a HIV cure, slamming media reports that promoted the untested claims of a drug manufacturer.

- Advertisement -

An Israeli drug company issued a media release claiming that a new drug Gammora had the potential to cure HIV. Zion Medical reported that they had administered their new drug to nine patients in Uganda and they had seen a 90% reduction in most patients.

“Most patients showed a significant reduction of the viral load of up to 90 per cent from the baseline during the first four weeks” the study noted. The participants then went on to combine the new drug with conventional antiretroviral treatments and increased their reduction to 99 per cent.

Experts have noted that this is no different to the results achieved by current treatments, which the participants were also tasking, and additional claims that the drug may have an ability to completely remove the virus were not backed by science.

“The HIV world has seen quackery in different forms for decades – sadly this smacks of more of it,” Professor Francois Venter of the University of Witwatersrand, South Africa told Health E-News.

“I looked at the press report and the unsophisticated company website, and even if you believe their claims, they are many years away from testing them,” he said. “This gives science and scientists a bad name.”

The study has not been presented at any scientific conference or been published in a peer reviewed journal, and experts have noted that the study only involved nine people and vaguely reports that “most” participants saw a reduction in viral load.

OIP Staff


 

Latest

UK Defence secretary Wes Streeting receives a deluge of anti-gay comments

Wes Streeting says he has faced a surge of online homophobic abuse since becoming Defence Secretary, despite progress in LGBTQ+ rights.

Equality Tasmania call on state government to step in and ensure health services continue

Equality Tasmania has raised concerns that key healthcare services could be affected following ACCC approval of Hobart Private's sale.

Nick Ward announces new album ‘Year of the Snake’

Nick Ward unveils 'Year Of The Snake', shares the Glenn Gould-sampling single 'Piano', and reflects on transformation and resilience.

Celebrated artist Yayoi Kusama dies aged 97

Polka-dot pioneer Yayoi Kusama, one of Japan's most influential modern artists, has died aged 97.

Newsletter

Don't miss

UK Defence secretary Wes Streeting receives a deluge of anti-gay comments

Wes Streeting says he has faced a surge of online homophobic abuse since becoming Defence Secretary, despite progress in LGBTQ+ rights.

Equality Tasmania call on state government to step in and ensure health services continue

Equality Tasmania has raised concerns that key healthcare services could be affected following ACCC approval of Hobart Private's sale.

Nick Ward announces new album ‘Year of the Snake’

Nick Ward unveils 'Year Of The Snake', shares the Glenn Gould-sampling single 'Piano', and reflects on transformation and resilience.

Celebrated artist Yayoi Kusama dies aged 97

Polka-dot pioneer Yayoi Kusama, one of Japan's most influential modern artists, has died aged 97.

Greens senator Sarah Hanson-Young’s brutal take down of Malcolm Roberts

Sarah Hanson-Young has criticised Malcolm Roberts after controversial comments about gay rights.

UK Defence secretary Wes Streeting receives a deluge of anti-gay comments

Wes Streeting says he has faced a surge of online homophobic abuse since becoming Defence Secretary, despite progress in LGBTQ+ rights.

Equality Tasmania call on state government to step in and ensure health services continue

Equality Tasmania has raised concerns that key healthcare services could be affected following ACCC approval of Hobart Private's sale.

Nick Ward announces new album ‘Year of the Snake’

Nick Ward unveils 'Year Of The Snake', shares the Glenn Gould-sampling single 'Piano', and reflects on transformation and resilience.